SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Catherine who wrote (11935)12/1/1997 10:02:00 AM
From: Henry Niman  Respond to of 32384
 
Catherine, Jim McCamant didn't mention LGND. He focused more on AGPH (buy under $40) and ISIP. Several end of the year bargain stocks were also mentioned as was IDPH (prompted by Joe Kernan). In conjunction with IDPH, CLTR was a plus (also targeting hon-Hodgkin's lymphoma) while ENMD was a minus for angiogenesis (lots of press but data only in mice). Angiogenises was then discussed with BBIOY being most advanced and AGPH having a phase I program.
McCamant also mentioned that he expected a Biotech rally to begin this week because of Robertson Stephen's conference (LGND presents there tomorrow).



To: Catherine who wrote (11935)12/1/1997 10:06:00 AM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
Catherine, Although LGND wasn't mentioned on CNBC, its definitely heading north. Bid is up to 13 1/4 and ask is 13 5/16 (it has already traded at 13 3/8).


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News